References
- Tackett S, Sugarman R, Kreuwel H, et al. Hospital economic impact from hemostatic matrix usage in cardiac surgery. J Med Econ 2014;17:670-6
- Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg 2009;88:1520-6
- Tackett S, Calcaterra D, Magee G, Lattouf OM. Real world outcomes of hemostatic matrices in cardiac surgery. J Cardiothorac Vasc Anesth 2014;28:1558-65
- Price JS, Tackett S, Patel V. Observational evaluation of outcomes and resource utilization from hemostatic matrices in spine surgery. J Med Econ 2015;18:777-86. Erratum in: J Med Econ 2016; 19:315-17
- Hu SS. Blood loss in spinal surgery. Eur Spine J 2004;13(Suppl 1):S3-S5
- FLOSEAL VH S/D Instructions for Use. Deerfield, IL: Baxter Healthcare Corporation; 2005
- SURGIFLO Instructions for Use. Somerville, NJ: J & J Wound Management; 2008
- Mozet C, Prettin C, Dietze M, et al. Use of floseal and effects on wound healing and pain in adults undergoing tonsillectomy: Randomised comparison versus electrocautery. Eur Arch Otorhinolaryngol 2012;269:2247-54
- Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surgeons 2007;205:256-65
- Lewis K, Atlee H, Mannone A, et al. Comparison of two gelatin and thrombin combination hemostats in a porcine liver abrasion model. J Invest Surg 2013;26:141-8
- Coenye KE, Bourgain C, Keibl C, et al. A qualitative morphological comparison of two haemostatic agents in a porcine liver trauma model. Surg Sci 2013;4:359-64
- HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2012. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed February 10, 2016
- David G, Lim S, Gunnarsson C, et al. Similar patient outcomes yet different hospital costs between flowable hemostatic agents. J Med Econ 2015;18:735-45
- Premier Inc: Premier PerspectiveTM Hospital Database. Charlotte, NC: Premier Inc.; 2012
- IMS Health. Hospital Supply Index. 2015. IMS America, Plymouth Meeting, PA
- Chatterjee A, Payette MJ, Demas CP, et al. Opportunity cost: a systematic application to surgery. Surgery 2009;146:18-22
- Landi A, Gregori F, Marotta N, et al. Efficacy, security, and manageability of gelified hemostatic matrix in bleeding control during thoracic and lumbar spine surgery: FloSeal versus Surgiflo. J Neurol Surg A Cent Eur Neurosurg 2016;77:139-43
- Faivre P, Laplante S, Kreuwel H. Multi European country cost consequence comparison of Floseal matrix and Surgiflo thrombin in major and severe spine surgeries. Value Health 2015;18:A370
- Makhija D, Rock M, Xiong Y, et al. Cost consequence analysis of two different active flowable hemostatic matrices in cardiac surgery patients (US hospital provider perspective). Poster Presentation at ISPOR 21st Annual International Meeting. Washington DC. May 23, 2016
- Bacchetta MD, Girardi LN, Southard EJ, et al. Comparison of open versus bedside percutaneous dilational tracheostomy in the cardiothoracic surgical patient: outcomes and financial analysis. Ann Thorac Surg 2005;79:1879-85
- Matin SF. Prospective randomized trial of skin adhesive versus sutures for closure of 217 laparoscopic port-site incisions. J Am Coll Surg 2003;196:845-53